In the near future, addressing baldness may become as straightforward as a daily hair combing routine. A team of researchers from Beihang University in China has developed a bioelectric device called Detangle, designed to treat alopecia during everyday personal hygiene practices.
Alopecia androgenetica, which leads to progressive hair loss and is linked to hormonal and genetic factors, affects over 1.5 billion people globally. It is the most prevalent form of baldness among men, with the initial signs emerging in approximately 25% of cases before the age of 21.
Currently, there are pharmacological treatments available for this condition; however, their effectiveness is often limited, and they can sometimes result in side effects impacting various parts of the body.
Innovative Approach to Hair Growth
Recent research published in Nature this month highlights how Detangle aims to overcome these challenges through a system that combines drug delivery with electrical impulses. The device’s goal is to stimulate hair growth and address the underlying factors that contribute to hair loss.
Detangle features electronic bristles equipped with electrodes positioned at varying heights, alongside small modules containing medication. According to the researchers, this configuration creates a localized electric field that aids in transporting the substances to the deeper regions of hair follicles, the skin structures where hair originates and grows.
In practical terms, the electric field serves dual purposes. It emits impulses that stimulate hair follicles and enhance their activity while also facilitating the delivery of two treatments directly into the cells of these structures.
The first treatment is a plasmid that carries genetic instructions to produce a protein known as VEGFA, which promotes the formation of new blood vessels. This process, referred to as angiogenesis, improves the supply of oxygen and nutrients to the tissues involved in hair growth.
The second component is a small fragment of genetic material called small interfering RNA (siRNA), designed to reduce the activity of the enzyme steroid 5-alpha-reductase type 2. This enzyme plays a role in the production of hormones that weaken and lead to the loss of hair follicles, a process associated with alopecia androgenetica.
Encouraging Results from Animal Trials
The efficacy of Detangle was evaluated in a trial involving mice that had been induced with alopecia. The mice were divided into two groups: one received treatment with the device, while the other was treated with conventional medications, minoxidil and finasteride. All the rodents had their backs shaved, and for a duration of 28 days, the respective treatments were applied.
The results indicated that after receiving a session every three days throughout the study period, the mice treated with the comb exhibited hair growth in nearly 100% of the shaved area, with no significant side effects. In contrast, the animals treated with minoxidil saw regrowth in about 70% of the area.
Based on these findings, the researchers assert that “the Detangle system has proven to be safe and effective for deep tissue administration in dermatology.” This capability could enhance the delivery of substances and medications directly to hair follicles, aiming to combat common baldness.
Future Research and Human Trials Needed
While specialists view these results as promising, positioning Detangle as a potential alternative for treating alopecia through a routine activity like combing hair, they also acknowledge the necessity for further research. Thus far, trials have only been conducted on mice, and it remains to be seen whether the device offers the same levels of safety and efficacy in humans.